

Supplemental Amendment
U.S.S.N. 09/292,217
Page 4 of 6

REMARKS

Applicant amends claims 1, 8, 20, 23 and 36. Accordingly, after entry of this Supplemental Amendment, claims 1, 2, 4-9, 12-24, 27 and 31-37 will be pending for examination.

Independent claims 1 and 20 are amended to recite a target cell in a solid tumor. Specifically, claims 1 and 20 now recite an immunoconjugate comprising an antibody site capable of binding a target antigen on a target cell in a solid tumor, thereby to induce a cytocidal immune response against the solid tumor.

Dependent claims 8 and 23 are amended to correct their antecedent basis based on amended claims 1 and 20 respectively.

Dependent claim 36 is amended to recite a target cell in a solid tumor.

Support for these amendments can be found in the specification as filed at least on page 3, lines 14-16; page 9, lines 20-23; and in Examples 1, 3, 4, 5 and 6.

Applicant submits that no new matter is introduced by these amendments.

CONCLUSION

Applicant submits that on the basis of the foregoing remarks and claim amendments, claims 1, 2, 4-9, 12-24, 27, and 31-37 are in condition for immediate allowance. Accordingly, Applicant respectfully requests entry as such. The Examiner is respectfully requested to call the undersigned at (617) 248-7240 prior to issuing a further Office action in this application, if necessary.

Respectfully submitted,

Pat R H Wall

Patrick R.H. Waller, Ph.D.
Attorney for the Applicant
Reg. No. 41,418

Date: August 22, 2002
Testa, Hurwitz & Thibeault
125 High Street
Boston, MA 02110
(617) 248-7240

2481093

Supplemental Amendment
U.S.S.N. 09/292,217
Page 5 of 6

MARKED-UP VERSION OF AMENDED CLAIMS SHOWING AMENDMENTS

1. (Three Times Amended) A method of inducing a cytoidal immune response against a solid tumor [target cell] in a mammal, the method comprising: administering to a mammal a combination of (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell in a solid tumor and interleukin 2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_1\beta_3$ integrin,

wherein the combination induces a cytoidal immune response against the solid tumor [target cell] that is greater than a response induced by the immunoconjugate alone.

8. (Three Times Amended) The method of claim 1, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell in a solid tumor, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) interleukin 2.

20. (Three Times Amended) A composition for inducing an immune response against a solid tumor [target cell] in a mammal, the composition comprising in combination: (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell in a solid tumor and interleukin-2, and (ii) an angiogenesis inhibitor having binding affinity for $\alpha_1\beta_3$ integrin,

wherein the combination induces a cytoidal immune response against the solid tumor [target cell] that is greater than a response induced by the immunoconjugate alone.

23. (Three Times Amended) The composition of claim 20, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell in a solid tumor, an immunoglobulin CH1 domain, an immunoglobulin CH2 domain, and (ii) interleukin-2.

Supplemental Amendment
U.S.S.N. 09/292,217
Page 6 of 6

36. (Three Times Amended) The method of claim 31, wherein the immunoconjugate is a fusion protein comprising, in an amino-terminal to carboxy-terminal direction, (i) the antibody binding site comprising an immunoglobulin variable region capable of binding a target antigen expressed on a target cell in a solid tumor, an immunoglobulin CH2 domain, and (ii) interleukin-2.